Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook

Type of publication: Academic publication
Disease:

Authors:

Anneliene Hechtelt Jonker, Virginie Hivert, Michela Gabaldo, Liliana Batista, Daniel O’Connor, Annemieke Aartsma-Rus, Simon Day, Ken Sakushima & Diego Ardigo


The International Rare Diseases Research Consortium (IRDiRC) has created a Guidebook to facilitate drug development for rare diseases by organizing available tools into a standardized framework. Millions of people worldwide are affected by rare diseases, but it is estimated that fewer than 5% of the known rare diseases have at least one approved pharmacotherapy1. Regulatory and economic incentives for the development of drugs for rare diseases (orphan drugs), have led to a steady rise in the number of such treatments2, but at the current pace, the International Rare Diseases Research Consortium (IRDiRC)’s goal3 of 1,000 new rare disease therapies by 2027 will not be reached. There are multiple challenges inherent in developing drugs for rare diseases, including the limited knowledge available for most diseases, the difficulties of generating adequate efficacy and safety data in small populations and the risk of financial unsustainability for both developers and health-care systems. In this context, the traditional model of development seems inefficient and a new framework is required. Over the past decade, research, policy, regulatory initiatives, resources and tools have been introduced to expedite drug development for rare diseases, such as stakeholder interaction programmes, innovative methodological and operational approaches for clinical trials and new development best practices. However, these tools are not yet systematically and coherently applied by all organizations in the field. This issue is increasingly important as a new generation of stakeholders, including charities and patient organizations, has arisen, which are often characterized by a strong focus and understanding of medical needs, but limited experience in managing the complexity of drug development.


Published: 20 April 2020
Journal: Nature Reviews Drug Discovery

Link: doi.org/10.1038/d41573-020-00060-w

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern